(Reuters) - European shares closed at their highest in almost two weeks on Tuesday, powered by cyclical stocks, following signs that business activity in the continent was rebounding faster than expected from a coronavirus-driven slump.
Euro zone stocks .STOXXE rose 1.6% after IHS Markit's Purchasing Managers' Index (PMI) showed a historic coronavirus-induced downturn in the bloc had eased again in June as businesses reopened after weeks of lockdown.
The index recovered more than expected to 47.5 from May’s 31.9, after touching a record low of 13.6 in April.
“It would no longer surprise me if the data is a surprise on the upside,” said Daniel McDonagh, head of European portfolio management team at Pyrford International, part of BMO Global Asset Management.
“The big question still is whether we can proceed on the exit strategy from the lockdown in a smooth manner and really avoid a step backwards.”
Investors also took relief as White House trade adviser Peter Navarro walked back from his earlier remarks that the Phase One trade deal with China was “over” and U.S. President Donald Trump confirmed in a tweet the trade deal was fully intact.
BlackRock’s Investment Institute said it was “warming up” to European assets following what it called the eurozone’s “impressive” efforts to tackle the coronavirus, and is considering an upgrade to European equities.
Trillions of dollars in stimulus from central banks and governments have helped the STOXX 600 recover nearly 37% from March lows, although the pace of recovery has slowed in June amid worries over a fresh rise in coronavirus cases.
Helping Germany's DAX outperform, Bayer AG BAYGn.DE gained 5.8% after reports that the company is set to reach a settlement this week with U.S. plaintiffs that claim its glyphosate-based weedkillers cause cancer.
German metals trader Kloeckner & Co KCOGn.DE jumped 17.5% after it provided positive earnings outlook for the second quarter.
Payments company Wirecard WDIG.DE, mired in an accounting scandal, bounced 18.8% after shedding more than 140% in the past three sessions.
UK-listed drugmaker Hikma Pharmaceuticals HIK.L fell 5.6% after a major shareholder sold most of its nearly 1 billion pound stake.
Reporting by Sruthi Shankar in Bengaluru; Editing by Anil D’Silva and Alexandra Hudson
Our Standards: The Thomson Reuters Trust Principles.